Related Experiment Video

Updated: May 25, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival

Martin Jenkins1, Andrew Stone, Christopher Jennison

  • 1AstraZeneca Pharmaceuticals, Global Clinical Development, Parklands, Alderley Park, Macclesfield, UK. Martin.Jenkins@astrazeneca.com

Pharmaceutical Statistics
|February 14, 2012
PubMed

Insights

This study introduces a flexible adaptive seamless design for clinical trials, enhancing patient subgroup and full population analysis. It ensures Type-I error control for correlated time-to-event endpoints in oncology settings.

Area of Science:

  • Clinical Trial Design
  • Biostatistics
  • Oncology Research

Background:

  • Adaptive seamless designs are crucial for efficient clinical trials.
  • Existing methods allow seamless continuation in subpopulations or the whole population.
  • Optimizing trial design requires careful selection of endpoints and specifications.

Purpose of the Study:

  • To introduce a novel adaptive seamless design with enhanced flexibility.
  • To allow continuation in both subgroup and full populations as co-primary objectives.
  • To present methodology for controlling Type-I error with distinct yet correlated time-to-event endpoints.

Main Methods:

  • Development of a flexible adaptive seamless design framework.
  • Methodology for Type-I error rate control (<2.5%) for correlated time-to-event endpoints.
  • Evaluation of operating characteristics and practical considerations.

Main Results:

  • The proposed design offers increased flexibility in adaptive seamless trials.
  • Co-primary populations (subgroup and full) can be maintained.
  • Effective Type-I error control is demonstrated for differing, correlated endpoints.

Conclusions:

  • The enhanced adaptive seamless design improves trial efficiency and flexibility.
  • This approach is particularly relevant for oncology clinical trials.
  • The methodology provides robust statistical control for complex endpoint scenarios.

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Study Designs in Epidemiology01:20

Study Designs in Epidemiology

Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and case-control studies.
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...